Journal of Korean Medical Science

Korean Acad Medical Sciences (대한의학회)
권호 표지
DOI QR코드

DOI QR Code

CDC6 mRNA Expression Is Associated with the Aggressiveness of Prostate Cancer

  • Kim, Ye-Hwan (Department of Urology, Chungbuk National University, College of Medicine) ;
  • Byun, Young Joon (Department of Urology, Chungbuk National University, College of Medicine) ;
  • Kim, Won Tae (Department of Urology, Chungbuk National University, College of Medicine) ;
  • Jeong, Pildu (Department of Urology, Chungbuk National University, College of Medicine) ;
  • Yan, Chunri (Department of Urology, Chungbuk National University, College of Medicine) ;
  • Kang, Ho Won (Department of Urology, Chungbuk National University, College of Medicine) ;
  • Kim, Yong-June (Department of Urology, Chungbuk National University, College of Medicine) ;
  • Lee, Sang-Cheol (Department of Urology, Chungbuk National University, College of Medicine) ;
  • Moon, Sung-Kwon (Department of Food and Nutrition, Chung-Ang University) ;
  • Choi, Yung-Hyun (Department of Biochemistry, Dongeui University College of Oriental Medicine) ;
  • Yun, Seok Joong (Department of Urology, Chungbuk National University, College of Medicine) ;
  • Kim, Wun-Jae (Department of Urology, Chungbuk National University, College of Medicine)
  • Received : 2017.12.29
  • Accepted : 2018.08.28
  • Published : 2018.11.19
⟨ Previous Next ⟩

Abstract

Background: Cell division cycle 6 (CDC6) is an essential regulator of DNA replication and plays important roles in the activation and maintenance of the checkpoint mechanisms in the cell cycle. CDC6 has been associated with oncogenic activities in human cancers; however, the clinical significance of CDC6 in prostate cancer (PCa) remains unclear. Therefore, we investigated whether the CDC6 mRNA expression level is a diagnostic and prognostic marker in PCa. Methods: The study subjects included 121 PCa patients and 66 age-matched benign prostatic hyperplasia (BPH) patients. CDC6 expression was evaluated using real-time polymerase chain reaction and immunohistochemical (IH) staining, and then compared according to the clinicopathological characteristics of PCa. Results: CDC6 mRNA expression was significantly higher in PCa tissues than in BPH control tissues (P = 0.005). In addition, CDC6 expression was significantly higher in patients with elevated prostate-specific antigen (PSA) levels (> 20 ng/mL), a high Gleason score, and advanced stage than in those with low PSA levels, a low Gleason score, and earlier stage, respectively. Multivariate logistic regression analysis showed that high expression of CDC6 was significantly associated with advanced stage (${\geq}T3b$) (odds ratio [OR], 3.005; confidence interval [CI], 1.212-7.450; P = 0.018) and metastasis (OR, 4.192; CI, 1.079-16.286; P = 0.038). Intense IH staining for CDC6 was significantly associated with a high Gleason score and advanced tumor stage including lymph node metastasis stage (linear-by-linear association, P = 0.044 and P = 0.003, respectively). Conclusion: CDC6 expression is associated with aggressive clinicopathological characteristics in PCa. CDC6 may be a potential diagnostic and prognostic marker in PCa patients.

Keywords

Acknowledgement

Supported by : Ministry of Science, ICT and Future Planning, National Research Foundation of Korea (NRF)

References

  1. Seo WI, Kang PM, Chung JI. Predictive value of the cancer of the prostate risk assessment score for recurrence-free survival after radical prostatectomy in Korea: a single-surgeon series. Korean J Urol 2014;55(5):321-6. https://doi.org/10.4111/kju.2014.55.5.321
  2. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90(10):766-71. https://doi.org/10.1093/jnci/90.10.766
  3. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277(18):1445-51. https://doi.org/10.1001/jama.1997.03540420041027
  4. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability--an evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010;11(3):220-8. https://doi.org/10.1038/nrm2858
  5. Charames GS, Bapat B. Genomic instability and cancer. Curr Mol Med 2003;3(7):589-96. https://doi.org/10.2174/1566524033479456
  6. Romanowski P, Madine MA. Mechanisms restricting DNA replication to once per cell cycle: MCMs, pre-replicative complexes and kinases. Trends Cell Biol 1996;6(5):184-8. https://doi.org/10.1016/0962-8924(96)10015-5
  7. Sasaki H, Kawano O, Endo K, Suzuki E, Yukiue H, Kobayashi Y, et al. Human MOB1 expression in non-small-cell lung cancer. Clin Lung Cancer 2007;8(4):273-6. https://doi.org/10.3816/CLC.2007.n.006
  8. Borlado LR, Mendez J. CDC6: from DNA replication to cell cycle checkpoints and oncogenesis. Carcinogenesis 2008;29(2):237-43. https://doi.org/10.1093/carcin/bgm268
  9. Hartwell LH. Sequential function of gene products relative to DNA synthesis in the yeast cell cycle. J Mol Biol 1976;104(4):803-17. https://doi.org/10.1016/0022-2836(76)90183-2
  10. Hateboer G, Wobst A, Petersen BO, Le Cam L, Vigo E, Sardet C, et al. Cell cycle-regulated expression of mammalian CDC6 is dependent on E2F. Mol Cell Biol 1998;18(11):6679-97. https://doi.org/10.1128/MCB.18.11.6679
  11. Ohtani K, Tsujimoto A, Ikeda M, Nakamura M. Regulation of cell growth-dependent expression of mammalian CDC6 gene by the cell cycle transcription factor E2F. Oncogene 1998;17(14):1777-85. https://doi.org/10.1038/sj.onc.1202105
  12. Yan Z, DeGregori J, Shohet R, Leone G, Stillman B, Nevins JR, et al. CDC6 is regulated by E2F and is essential for DNA replication in mammalian cells. Proc Natl hAcad Sci U S A 1998;95(7):3603-8. https://doi.org/10.1073/pnas.95.7.3603
  13. Ohta S, Koide M, Tokuyama T, Yokota N, Nishizawa S, Namba H. CDC6 expression as a marker of proliferative activity in brain tumors. Oncol Rep 2001;8(5):1063-6.
  14. Xiong XD, Fang JH, Qiu FE, Zhao J, Cheng J, Yuan Y, et al. A novel functional polymorphism in the CDC6 promoter is associated with the risk for hepatocellular carcinoma. Mutat Res 2008;643(1-2):70-4. https://doi.org/10.1016/j.mrfmmm.2008.06.006
  15. Zhang X, Xiao D, Wang Z, Zou Y, Huang L, Lin W, et al. MicroRNA-26a/b regulate DNA replication licensing, tumorigenesis, and prognosis by targeting CDC6 in lung cancer. Mol Cancer Res 2014;12(11):1535-46. https://doi.org/10.1158/1541-7786.MCR-13-0641
  16. Deng Y, Jiang L, Wang Y, Xi Q, Zhong J, Liu J, et al. High expression of CDC6 is associated with accelerated cell proliferation and poor prognosis of epithelial ovarian cancer. Pathol Res Pract 2016;212(4):239-46. https://doi.org/10.1016/j.prp.2015.09.014
  17. Sun TY, Xie HJ, He H, Li Z, Kong LF. miR-26a inhibits the proliferation of ovarian cancer cells via regulating CDC6 expression. Am J Transl Res 2016;8(2):1037-46.
  18. Liu Y, Gong Z, Sun L, Li X. FOXM1 and androgen receptor co-regulate CDC6 gene transcription and DNA replication in prostate cancer cells. Biochim Biophys Acta 2014;1839(4):297-305. https://doi.org/10.1016/j.bbagrm.2014.02.016
  19. Williams RS, Shohet RV, Stillman B. A human protein related to yeast Cdc6p. Proc Natl Acad Sci U S A 1997;94(1):142-7. https://doi.org/10.1073/pnas.94.1.142
  20. Niimi S, Arakawa-Takeuchi S, Uranbileg B, Park JH, Jinno S, Okayama H. CDC6 protein obstructs apoptosome assembly and consequent cell death by forming stable complexes with activated Apaf-1 molecules. J Biol Chem 2012;287(22):18573-83. https://doi.org/10.1074/jbc.M112.347690
  21. Piatti S, Lengauer C, Nasmyth K. CDC6 is an unstable protein whose de novo synthesis in G1 is important for the onset of S phase and for preventing a 'reductional' anaphase in the budding yeast Saccharomyces cerevisiae. EMBO J 1995;14(15):3788-99. https://doi.org/10.1002/j.1460-2075.1995.tb00048.x
  22. Feng CJ, Lu XW, Luo DY, Li HJ, Guo JB. Knockdown of CDC6 inhibits proliferation of tongue squamous cell carcinoma Tca8113 cells. Technol Cancer Res Treat 2013;12(2):173-81. https://doi.org/10.7785/tcrt.2012.500302
  23. Jin F, Fondell JD. A novel androgen receptor-binding element modulates CDC6 transcription in prostate cancer cells during cell-cycle progression. Nucleic Acids Res 2009;37(14):4826-38. https://doi.org/10.1093/nar/gkp510
  24. Xiong XD, Zeng LQ, Xiong QY, Lu SX, Zhang ZZ, Luo XP, et al. Association between the CDC6 G1321A polymorphism and the risk of cervical cancer. Int J Gynecol Cancer 2010;20(5):856-61. https://doi.org/10.1111/IGC.0b013e3181df3cab
  25. Martin CM, Astbury K, McEvoy L, O'Toole S, Sheils O, O'Leary JJ. Gene expression profiling in cervical cancer: identification of novel markers for disease diagnosis and therapy. Methods Mol Biol 2009;511:333-59.
  26. Feng CJ, Li HJ, Li JN, Lu YJ, Liao GQ. Expression of Mcm7 and CDC6 in oral squamous cell carcinoma and precancerous lesions. Anticancer Res 2008;28(6A):3763-9.
  27. Makarov DV, Sanderson H, Partin AW, Epstein JI. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores? J Urol 2002;167(6):2440-2. https://doi.org/10.1016/S0022-5347(05)65000-8
  28. Kang HW, Jung HD, Lee JY, Kwon JK, Jeh SU, Cho KS, et al. The Within-Group Discrimination Ability of the Cancer of the Prostate Risk Assessment Score for Men with Intermediate-Risk Prostate Cancer. J Korean Med Sci 2018;33(5):e36. https://doi.org/10.3346/jkms.2018.33.e36
  29. Ruckle HC, Klee GG, Oesterling JE. Prostate-specific antigen: concepts for staging prostate cancer and monitoring response to therapy. Mayo Clin Proc 1994;69(1):69-79. https://doi.org/10.1016/S0025-6196(12)61615-2

Cited by

  1. Association between tumor necrosis factor-alpha gene rs1800629 (-308G/A) and rs361525 (-238G > A) polymorphisms and prostate cancer risk in an Iranian cohort vol.28, pp.1, 2018, https://doi.org/10.3233/hab-190397
  2. miR‐215‐5p decreases migration and invasion of trophoblast cells through regulating CDC6 in preeclampsia vol.38, pp.4, 2018, https://doi.org/10.1002/cbf.3492
  3. A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specifi vol.61, pp.4, 2018, https://doi.org/10.4111/icu.2020.61.4.411
  4. MiR-128-3p suppresses tumor proliferation and metastasis via targeting CDC6 in hepatocellular carcinoma cells vol.72, pp.None, 2021, https://doi.org/10.1016/j.tice.2021.101534
  5. MiR-128-3p suppresses tumor proliferation and metastasis via targeting CDC6 in hepatocellular carcinoma cells vol.72, pp.None, 2021, https://doi.org/10.1016/j.tice.2021.101534
  6. Identification of biomarkers related to glycolysis with weighted gene co‐expression network analysis in oral squamous cell carcinoma vol.44, pp.1, 2022, https://doi.org/10.1002/hed.26910